Holen Sie sich die Stockscreener-App
6.99
0.99%
-0.07
Vorhandelsmarkt:
7.10
0.11
+1.57%
Schlusskurs vom Vortag:
$7.06
Offen:
$7.06
24-Stunden-Volumen:
145.98K
Relative Volume:
0.51
Marktkapitalisierung:
$153.28M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-52.07M
KGV:
-33.65
EPS:
-0.2077
Netto-Cashflow:
$-44.93M
1W Leistung:
-4.90%
1M Leistung:
-3.05%
6M Leistung:
-32.85%
1J Leistung:
-46.84%
1-Tages-Spanne:
$6.91
$7.20
1-Wochen-Bereich:
$6.83
$7.85
52-Wochen-Spanne:
$4.81
$14.44
Cybin Inc Stock (CYBN) Company Profile
Firmenname
Cybin Inc
Sektor
Branche
Telefon
908 764 8385
Adresse
100 King Street West, Suite 5600, Toronto
Vergleichen Sie CYBN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CYBN
Cybin Inc
|
6.99 | 153.28M | 0 | -52.07M | -44.93M | -0.2077 |
|
VRTX
Vertex Pharmaceuticals Inc
|
493.84 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
602.64 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
614.76 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.56 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
244.90 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Cybin Inc Stock (CYBN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-13 | Eingeleitet | Guggenheim | Buy |
| 2021-11-19 | Herabstufung | Maxim Group | Buy → Hold |
Cybin Inc Aktie (CYBN) Neueste Nachrichten
Weekly Roundup on the Cannabis Sector & Psychedelic Sector - marketexclusive.com
Cybin advances Phase 3 trial for depression treatment By Investing.com - Investing.com South Africa
Cybin Announces Additional Strategic Clinical Site Partnerships - GuruFocus
Cybin Expands Strategic Partnerships for Phase 3 MDD Treatment Trials - TipRanks
Cybin (CYBN) Expands Strategic Partnerships for Phase 3 MDD Program | CYBN Stock News - GuruFocus
Cybin advances Phase 3 trial for depression treatment - Investing.com
Cybin Says Second Phase 3 Study Embrace Expected To Begin Mid-2025 - marketscreener.com
CYBNCybin Inc Latest Stock News & Market Updates - Stock Titan
Cybin Announces Additional Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Phase 3 Program Evaluating CYB003 - The Joplin Globe
(CYBN) Trading Report - news.stocktradersdaily.com
Cybin (CYBN) Partners with Osmind for Psychedelic Therapy Launch - GuruFocus
Psychedelic drug developer Cybin partners with Osmind (CYBN:NYSE) - Seeking Alpha
Cybin Partners with Osmind to Accelerate Commercial Preparation for its Clinical-Stage Psychiatry Programs - 01net
Cybin Partners With Osmind to Support Psychiatry Program Pipeline - marketscreener.com
Cybin Partners with Osmind to Accelerate Commercial Preparation for its Clinical-Stage Psychiatry Programs | CYBN Stock News - GuruFocus
Cybin's Game-Changing Mental Health Partnership: 800+ Clinics to Deploy Novel Depression and Anxiety Treatments - Stock Titan
Where are the Opportunities in (CYBN) - news.stocktradersdaily.com
Filament Health secures investment to remedy concerning financial position - Mugglehead Magazine
4 Psychedelic Stocks to Buy Now - The Motley Fool
CYBN Stock Forecast: Projections From 2025 To 2040 - Exla Resources
Cybin to Participate in Cowen’s Psychedelics & Novel Mechanisms in Neuropsychiatry Virtual Summit on July 13th - Business Wire
Cybin wins new Buy from Guggenheim: potential to challenge J&J’s Spravato cited - MSN
(CYBN) Investment Analysis and Advice - news.stocktradersdaily.com
Guggenheim Initiates Coverage of Cybin (CYBN) with Buy Recommendation - Nasdaq
Cybin initiated with a Buy at Guggenheim - TipRanks
Cybin Inc. Reports Q3 2025 Financial Results and Strategic Progress - TipRanks
Psychedelic Science 2025 Announces Select Speakers for the Leading Conference on Psychedelic Research, Policy, and Thought Leadership - GlobeNewswire Inc.
Cybin Inc. (CYBN) Loses -25.81% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Nasdaq
Cybin Inc. (CYBN): Among the Best Psychedelic Stocks to Buy in 2025 - Insider Monkey
12 Best Psychedelic Stocks to Buy in 2025 - Insider Monkey
Wall Street Analysts Think Cybin Inc. (CYBN) Could Surge 988.67%: Read This Before Placing a Bet - MSN
Cybin (OTCMKTS:CLXPF) Shares Down 2.5%Here's What Happened - MarketBeat
How to Take Advantage of moves in (CYBN) - news.stocktradersdaily.com
Revolutionizing Mental Health Through Psychedelic Therapeutics | by Dr. Gleb Tsipursky | Feb, 2025 - DataDrivenInvestor
Cybin (NYSE:CYBN) Price Target Cut to $150.00 by Analysts at HC Wainwright - MarketBeat
Cybin (OTCMKTS:CYBN) Trading Up 1.2%Here's Why - MarketBeat
Canaccord cuts Cybin stock target to $73, maintains Buy rating - MSN
Cybin (NYSE:CYBN) Price Target Lowered to $73.00 at Canaccord Genuity Group - MarketBeat
Cybin stock price target cut to $150 at H.C. Wainwright - MSN
Cybin stock price target cut to $150 at H.C. Wainwright By Investing.com - Investing.com Australia
Canaccord cuts Cybin stock target to $73, maintains Buy rating By Investing.com - Investing.com Nigeria
(CYBN) Investment Analysis - Stock Traders Daily
Finanzdaten der Cybin Inc-Aktie (CYBN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.24%
36.06%
Kapitalisierung:
|
Volumen (24h):